PMV Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PMVP | VTVT | INO | PMRA.F | MNOV | PLRX | |
|---|---|---|---|---|---|---|
| Market cap | 100.05M | 95.01M | 167.50M | 1.17B | 71.37M | 52.75M |
| P/E (TTM) | — | — | — | 17.3 | — | — |
| Forward P/E | -1.5 | -5.5 | -3.9 | — | -2.8 | -0.7 |
| Price/book | 1.0 | 3.8 | 30.6 | 5.0 | 1.9 | 0.4 |
| Dividend yield | — | — | — | 1.54% | — | — |
| 1-year change | +6.00% | −5.65% | −27.51% | −9.28% | +3.57% | −47.50% |
| Today | −3.99% | +2.04% | −2.41% | +6.01% | +2.11% | −1.03% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All PMVP news ›PMV Pharmaceuticals (PMVP) Projected to Announce Earnings on Wednesday
Posted by Danessa Lincoln on Nov 4th, 2026 PMV Pharmaceuticals (NASDAQ:PMVP – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping…
PMV Pharmaceuticals (NASDAQ:PMVP) Upgraded to Hold at Wall Street Zen
Posted by Tristan Rich on Oct 31st, 2026 PMV Pharmaceuticals (NASDAQ:PMVP – Get Free Report) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.…
PMV Pharmaceuticals (NASDAQ:PMVP) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell?
Posted by Michael Walen on Oct 31st, 2026 PMV Pharmaceuticals, Inc. (NASDAQ:PMVP – Get Free Report) shares crossed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of…
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock Has Average Price Target of $4.33
Posted by Defense World Staff on Oct 27th, 2026 Get Our Latest Report on PMVP PMV Pharmaceuticals (NASDAQ:PMVP – Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.34) earnings per…
Processa Pharmaceuticals acquires Vidya, raises strategic funding
The latest announcement is out from Processa Pharmaceuticals ( (PCSA) ). The most recent analyst rating on (PCSA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Processa Pharmaceuticals stock, see…
PMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer Opportunity
PMV Pharmaceuticals is rated Buy, targeting $3–$4/share, driven by Rezatapopt's 46% response rate. Click to read more about the PMVP stock. - PMV Pharmaceuticals is rated Buy, targeting $3–$4/share, driven by rezatapopt’s 46% response rate…
PMV Pharmaceuticals Director Matthew Joseph Eckler Granted 84,000 Stock Options
kalkinemedia.com A Form 4 filed with the SEC on October 5, 2026, reveals that Matthew Joseph Eckler, a director at PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) PMVP (NASDAQ:PMVP) , was awarded a stock option grant on October
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock Rated “Moderate Buy” by Wall Street Analysts
Posted by Michael Walen on Oct 6th, 2026 View Our Latest Stock Report on PMV Pharmaceuticals PMV Pharmaceuticals (NASDAQ:PMVP – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.34) EPS for…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com5
- defenseworld.net1
- seekingalpha.com1
- theglobeandmail.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.